Normal view MARC view ISBD view

Evolving role of immunotherapy in small cell lung cancer. [Review]

MedStar author(s):

Citation: Seminars in Cancer Biology. 2022 Feb 19PMID: 35192928Department: Hematology & Oncology Fellowship D | Hematology & Oncology Fellowship J | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewYear: 2022 ISSN:

1044-579X

Name of journal: Seminars in cancer biologyAbstract: Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly poor prognosis. For decades, the best available systemic therapy was platinum plus etoposide chemotherapy, which offered frequent but transient responses. Survival gains were finally realized with the addition of immune checkpoint inhibitors to first-line chemotherapy. The phase III IMpower 133 trial showed that the addition of atezolizumab to chemotherapy improved survival. The subsequent CASPIAN trial demonstrated a similar benefit with durvalumab. These results quickly established chemo-immunotherapy as the preferred initial treatment for advanced SCLC, but outcomes remain poor for most patients. Here, we review the current and evolving role of immunotherapy in SCLC and outline emerging strategies poised to further elevate the standard of care. Copyright © 2022 Elsevier Ltd. All rights reserved.All authors: Barrows ED, Blackburn MJ, Liu SVFiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.1016/j.semcancer.2022.02.021

Date added to catalog: 2022-03-17

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35192928	Available		35192928

Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly poor prognosis. For decades, the best available systemic therapy was platinum plus etoposide chemotherapy, which offered frequent but transient responses. Survival gains were finally realized with the addition of immune checkpoint inhibitors to first-line chemotherapy. The phase III IMpower 133 trial showed that the addition of atezolizumab to chemotherapy improved survival. The subsequent CASPIAN trial demonstrated a similar benefit with durvalumab. These results quickly established chemo-immunotherapy as the preferred initial treatment for advanced SCLC, but outcomes remain poor for most patients. Here, we review the current and evolving role of immunotherapy in SCLC and outline emerging strategies poised to further elevate the standard of care. Copyright © 2022 Elsevier Ltd. All rights reserved.

English